Evaluation of chronic pruritus in older patients

Aging Health

Volumn 6, Issue 1, 2010, Pages 53-66

  Grundmann, Sonja A ^a   Ständer, Sonja ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Aged; Dermatitis; Geriatric; Itch; Prurigo; Pruritus; Skin aging; Therapy

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CALCINEURIN INHIBITOR; CAMPHOR; CANNABINOID RECEPTOR AGONIST; CAPSAICIN; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN A; DESLORATADINE; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; GABAPENTIN; GLUCOCORTICOID; HUMECTANT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MENTHOL; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; MONTELUKAST; PALMIDROL; PIMECROLIMUS; POLIDOCANOL; PREGABALIN; PSORALEN; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AGED; AGING; ATOPIC DERMATITIS; CHRONIC PRURITUS; COMORBIDITY; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIZZINESS; DRUG CHOICE; DRUG DOSE TITRATION; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; HAND ECZEMA; HUMAN; HYPERTENSION; LICHEN SCLEROSUS ET ATROPHICUS; LOW DRUG DOSE; MENTAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PERIPHERAL EDEMA; PHOTOTHERAPY; POLYPHARMACY; PREVALENCE; PRURIGO; PRURITUS; PSORIASIS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RASH; REVIEW; ROSACEA; SCROTUM DISORDER; SKIN DISEASE; SYMPTOM; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 77949586810     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.09.84     Document Type: Review

References (158)

1. US Census Bureau: Census 2000. US Census Bureau, Washington, DC, USA (2000).
2. Office for National Statistics: 2006-Based National Populations Projections. Office for National Statistics, London, UK (2006).
3. Bundesamt Für Statistik: Bevölkerung Deutschlands bis 2050. Bundesamt Für Statistik, Wiesbaden, Germany (2006).
4. Farage MA, Miller KW, Elsner P, Maibach HI: Functional and physiological characteristics of the aging skin. Aging Clin. Exp. Res. 20(3), 195-200 (2008).
5. Dalgard F, Svensson A, Holm JO, Sundby J: Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br. J. Dermatol. 151(2), 452-457 (2004).
6. Sommer F, Hensen P, Bockenholt B, Metze D, Luger TA, Stander S: Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm. Venereol. 87(6), 510-516 (2007).
7. Yosipovitch G, Greaves MW, Schmelz M: Itch. Lancet 361(9358), 690-694 (2003).
8. Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, Roujeau JC, Revuz J: French people and skin diseases: results of a survey using a representative sample. Arch. Dermatol. 139(12), 1614-1619; Discussion 1619 (2003).
9. Matterne U, Strassner T, Apfelbacher CJ, Diepgen TL, Weisshaar E: Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large-scale studies. Acta Derm. Venereol. 89(3), 250-256 (2009).
10. Meding B, Liden C, Berglind N: Self-diagnosed dermatitis in adults. Results from a population survey in Stockholm. Contact Derm. 45(6), 341-345 (2001).
11. Yalcin B, Tamer E, Toy GG, Oztas P, Hayran M, Alli N: The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int. J. Dermatol. 45(6), 672-676 (2006).
12. Thaipisuttikul Y: Pruritic skin diseases in the elderly. J. Dermatol. 25(3), 153-157 (1998).
13. Greaves MW, Khalifa N: Itch: more than skin deep. Int. Arch. Allergy Immunol. 135(2), 166-172 (2004).
14. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T: Neurophysiology of pruritus: cutaneous elicitation of itch. Arch. Dermatol. 139(11), 1463-1470 (2003).
15. Stander S, Weisshaar E, Mettang T et al.: Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm. Venereol. 87(4), 291-294 (2007).
16. Hashiro M, Okumura M: Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. J. Dermatol. Sci. 14(1), 63-67 (1997).
17. Sheehan-Dare RA, Henderson MJ, Cotterill JA: Anxiety and depression in patients with chronic urticaria and generalized pruritus. Br. J. Dermatol. 123(6), 769-774 (1990).
18. Weisshaar E, Apfelbacher C, Jager G et al.: Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br. J. Dermatol. 155(5), 957-964 (2006).
19. Bigby M, Jick S, Jick H, Arndt K: Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256(24), 3358-3363 (1986).
20. Kantor GR, Lookingbill DP: Generalized pruritus and systemic disease. J. Am. Acad. Dermatol. 9(3), 375-382 (1983).
21. Mazeh D, Melamed Y, Cholostoy A, Aharonovitzch V, Weizman A, Yosipovitch G: Itching in the psychiatric ward. Acta Derm. Venereol. 88(2), 128-131 (2008).
22. Stander S: Chronic pruritus: principals of diagnostics and therapy. Hautarzt 58(7), 627-636 (2007).
23. Bernhard JD: Itch and pruritus: what are they, and how should itches be classified? Dermatol. Ther. 18(4), 288-291 (2005).
24. Stander S, Weisshaar E, Mettang T et al.: [Clinical classification of chronic pruritus. Interdisciplinary consensus proposal for a diagnostic algorithm]. Hautarzt 57(5), 390-394 (2006).
25. Twycross R, Greaves MW, Handwerker H et al.: Itch: scratching more than the surface. QJM 96(1), 7-26 (2003).
26. Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ: Pathophysiology of premature skin aging induced by ultraviolet light. N. Engl. J. Med. 337(20), 1419-1428 (1997).
27. Landau M: Exogenous factors in skin aging. Curr. Probl. Dermatol. 35, 1-13 (2007).
28. Uitto J: The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J. Drugs Dermatol. 7(Suppl. 2), S12-S16 (2008).
29. Jenkins G: Molecular mechanisms of skin ageing. Mech. Ageing Dev. 123(7), 801-810 (2002).
30. Farage MA, Miller KW, Elsner P, Maibach HI: Structural characteristics of the aging skin: a review. Cutan. Ocul. Toxicol. 26(4), 343-357 (2007).
31. Farage MA, Miller KW, Elsner P, Maibach HI: Intrinsic and extrinsic factors in skin ageing: a review. Int. J. Cosmet. Sci. 30(2), 87-95 (2008).
32. Waller JM, Maibach HI: Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res. Technol. 11(4), 221-235 (2005).
33. Waller JM, Maibach HI: Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res. Technol. 12(3), 145-154 (2006).
34. Akimoto K, Yoshikawa N, Higaki Y, Kawashima M, Imokawa G: Quantitative analysis of stratum corneum lipids in xerosis and asteatotic eczema. J. Dermatol. 20(1), 1-6 (1993).
35. Brocq LAJ: Traité Elémentaire de Dermatologie Pratique Comprenant les Syphilides Cutanées [Basic disquisition on practical dermatology including cutaneous forms of syphilis]. Paris Octave Doin, Paris, France (1907).
36. Duque MI, Yosipovitch G, Chan YH, Smith R, Levy P: Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life. J. Am. Acad. Dermatol. 53(3), 504-508 (2005).
37. Rashtak S, Pittelkow MR: Skin involvement in systemic autoimmune diseases. Curr. Dir. Autoimmun. 10, 344-358 (2008).
38. Lee JJ, Downham TF 2nd: Furosemide-induced bullous pemphigoid: case report and review of literature. J. Drugs Dermatol. 5(6), 562-564 (2006).
39. Loo WJ, Burrows NP: Management of autoimmune skin disorders in the elderly. Drugs Aging 21(12), 767-777 (2004).
40. Mutasim DF: Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging 20(9), 663-681 (2003).
41. Rothe MJ, Bernstein ML, Grant-Kels JM: Life-threatening erythroderma: diagnosing and treating the 'red man'. Clin. Dermatol. 23(2), 206-217 (2005).
42. Sullivan JR, Shear NH: Drug eruptions and other adverse drug effects in aged skin. Clin. Geriatr. Med. 18(1), 21-42 (2002).
43. Norman R: HIV and Aging, Dermatology Clinical Geriatrics. Norman R, Dharmarajan T (Eds). CRC Press, Parthenon Publishing, FL, USA, 655-660 (2003).
44. Grabowski G, Kanhai A, Grabowski R, Holewinski J, Williams ML: Norwegian scabies in the immunocompromised patient. J. Am. Podiatr. Med. Assoc. 94(6), 583-586 (2004).
45. Weisshaar E, Kucenic MJ, Fleischer AB Jr: Pruritus: a review. Acta Derm. Venereol. Suppl. (Stockh.) (213), 5-32 (2003).
46. Masi CM, Cohen EP: Dialysis efficacy and itching in renal failure. Nephron 62(3), 257-261 (1992).
47. Mistik S, Utas S, Ferahbas A et al.: An epidemiology study of patients with uremic pruritus. J. Eur. Acad. Dermatol. Venereol. 20(6), 672-678 (2006).
48. Murphy M, Carmichael AJ: Renal itch. Clin. Exp. Dermatol. 25(2), 103-106 (2000).
49. Keithi-Reddy SR, Patel TV, Armstrong AW, Singh AK: Uremic pruritus. Kidney Int. 72(3), 373-377 (2007).
50. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR: Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N. Engl. J. Med. 279(13), 697-700 (1968).
51. Momose A, Kudo S, Sato M et al.: Calcium ions are abnormally distributed in the skin of haemodialysis patients with uraemic pruritus. Nephrol. Dial. Transplant. 19(8), 2061-2066 (2004).
52. Zucker I, Yosipovitch G, David M, Gafter U, Boner G: Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J. Am. Acad. Dermatol. 49(5), 842-846 (2003).
53. Bergasa NV, Mehlman JK, Jones EA: Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14(4), 643-655 (2000).
54. Heathcote EJ: Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31(4), 1005-1013 (2000).
55. Bergasa NV: Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin. Liver Dis. 12(2), 385-406 (2008).
56. Bergasa NV: Update on the treatment of the pruritus of cholestasis. Clin. Liver Dis. 12(1), 219-234 (2008).
57. Al-Mutairi N, Zaki A, Sharma AK, Al-Sheltawi M: Cutaneous manifestations of diabetes mellitus. Study from Farwaniya hospital, Kuwait. Med. Princ. Pract. 15(6), 427-430 (2006).
58. Neilly JB, Martin A, Simpson N, MacCuish AC: Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care 9(3), 273-275 (1986).
59. Yosipovitch G, Hodak E, Vardi P et al.: The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 21(4), 506-509 (1998).
60. Feiner AS, Mahmood T, Wallner SF: Prognostic importance of pruritus in Hodgkin's disease. JAMA 240(25), 2738-2740 (1978).
61. Robak E, Robak T: Skin lesions in chronic lymphocytic leukemia. Leuk. Lymphoma 48(5), 855-865 (2007).
62. Dalgard F, Lien L, Dalen I: Itch in the community: associations with psychosocial factors among adults. J. Eur. Acad. Dermatol. Venereol. 21(9), 1215-1219 (2007).
63. Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Stander S: Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin. Exp. Dermatol. 31(6), 762-767 (2006).
64. Krishnan A, Koo J: Psyche, opioids, and itch: therapeutic consequences. Dermatol. Ther. 18(4), 314-322 (2005).
65. Kimyai-Asadi A, Nousari HC, Kimyai-Asadi T, Milani F: Poststroke pruritus. Stroke 30(3), 692-693 (1999).
66. Wahlgren CF: Itch and atopic dermatitis: clinical and experimental studies. Acta Derm. Venereol. Suppl. (Stockh.) 165, 1-53 (1991).
67. Hagermark O, Wahlgren CF: Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. J. Dermatol. Sci. 4(2), 55-62 (1992).
68. Saurat JH: Dermatoporosis. The functional side of skin aging. Dermatology 215(4), 271-272 (2007).
69. Norman R: Xerosis and pruritus in the elderly. Dermatol. Ther. 16(3), 254-259 (2003).
70. Norman RA: Xerosis and pruritus in the elderly - recognition and management. In: Diagnosis of Aging Skin Diseases. Norman RA (Ed.). Springer Publishing, London, UK 151-159 (2008).
71. Bromm B, Scharein E, Darsow U, Ring J: Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci. Lett. 187(3), 157-160 (1995).
72. Fleischer AB: The Clinical Management of Itching. Fleischer AB (Ed.). Informa Healthcare, NY, USA (2000).
73. Hagermark O, Wahlgren CF: Treatment of itch. Semin. Dermatol. 14(4), 320-325 (1995).
74. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI: Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol. Appl. Skin Physiol. 13(6), 352-357 (2000).
75. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S: Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br. J. Dermatol. 148(6), 1212-1221 (2003).
76. Waller JM, Maibach HI: Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res. Technol. 12(3), 145-154 (2006).
77. Akimoto K, Yoshikawa N, Higaki Y, Kawashima M, Imokawa G: Quantitative analysis of stratum corneum lipids in xerosis and asteatotic eczema. J. Dermatol. 20(1), 1-6 (1993).
78. Brocq LAJ: Traité Elémentaire de Dermatologie Pratique Comprenant les Syphilides Cutanées [Basic disquisition on practical dermatology including cutaneous forms of syphilis]. Paris Octave Doin, Paris, France (1907).
79. Duque MI, Yosipovitch G, Chan YH, Smith R, Levy P: Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life. J. Am. Acad. Dermatol. 53(3), 504-508 (2005).
80. Rashtak S, Pittelkow MR: Skin involvement in systemic autoimmune diseases. Curr. Dir. Autoimmun. 10, 344-358 (2008).
81. Lee JJ, Downham TF 2nd: Furosemide-induced bullous pemphigoid: case report and review of literature. J. Drugs Dermatol. 5(6), 562-564 (2006).
82. Loo WJ, Burrows NP: Management of autoimmune skin disorders in the elderly. Drugs Aging 21(12), 767-777 (2004).
83. Mutasim DF: Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging 20(9), 663-681 (2003).
84. Rothe MJ, Bernstein ML, Grant-Kels JM: Life-threatening erythroderma: diagnosing and treating the 'red man'. Clin. Dermatol. 23(2), 206-217 (2005).
85. Sullivan JR, Shear NH: Drug eruptions and other adverse drug effects in aged skin. Clin. Geriatr. Med. 18(1), 21-42 (2002).
86. Norman R: HIV and Aging, Dermatology Clinical Geriatrics. Norman R, Dharmarajan T (Eds). CRC Press, Parthenon Publishing, FL, USA, 655-660 (2003).
87. Grabowski G, Kanhai A, Grabowski R, Holewinski J, Williams ML: Norwegian scabies in the immunocompromised patient. J. Am. Podiatr. Med. Assoc. 94(6), 583-586 (2004).
88. Weisshaar E, Kucenic MJ, Fleischer AB Jr: Pruritus: a review. Acta Derm. Venereol. Suppl. (Stockh.) (213), 5-32 (2003).
89. Masi CM, Cohen EP: Dialysis efficacy and itching in renal failure. Nephron 62(3), 257-261 (1992).
90. Mistik S, Utas S, Ferahbas A et al.: An epidemiology study of patients with uremic pruritus. J. Eur. Acad. Dermatol. Venereol. 20(6), 672-678 (2006).
91. Murphy M, Carmichael AJ: Renal itch. Clin. Exp. Dermatol. 25(2), 103-106 (2000).
92. Keithi-Reddy SR, Patel TV, Armstrong AW, Singh AK: Uremic pruritus. Kidney Int. 72(3), 373-377 (2007).
93. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR: Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N. Engl. J. Med. 279(13), 697-700 (1968).
94. Momose A, Kudo S, Sato M et al.: Calcium ions are abnormally distributed in the skin of haemodialysis patients with uraemic pruritus. Nephrol. Dial. Transplant. 19(8), 2061-2066 (2004).
95. Zucker I, Yosipovitch G, David M, Gafter U, Boner G: Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J. Am. Acad. Dermatol. 49(5), 842-846 (2003).
96. Bergasa NV, Mehlman JK, Jones EA: Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14(4), 643-655 (2000).
97. Heathcote EJ: Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31(4), 1005-1013 (2000).
98. Bergasa NV: Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin. Liver Dis. 12(2), 385-406 (2008).
99. Bergasa NV: Update on the treatment of the pruritus of cholestasis. Clin. Liver Dis. 12(1), 219-234 (2008).
100. Al-Mutairi N, Zaki A, Sharma AK, Al-Sheltawi M: Cutaneous manifestations of diabetes mellitus. Study from Farwaniya hospital, Kuwait. Med. Princ. Pract. 15(6), 427-430 (2006).
101. Neilly JB, Martin A, Simpson N, MacCuish AC: Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care 9(3), 273-275 (1986).
102. Yosipovitch G, Hodak E, Vardi P et al.: The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 21(4), 506-509 (1998).
103. Feiner AS, Mahmood T, Wallner SF: Prognostic importance of pruritus in Hodgkin's disease. JAMA 240(25), 2738-2740 (1978).
104. Robak E, Robak T: Skin lesions in chronic lymphocytic leukemia. Leuk. Lymphoma 48(5), 855-865 (2007).
105. Dalgard F, Lien L, Dalen I: Itch in the community: associations with psychosocial factors among adults. J. Eur. Acad. Dermatol. Venereol. 21(9), 1215-1219 (2007).
106. Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Stander S: Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin. Exp. Dermatol. 31(6), 762-767 (2006).
107. Krishnan A, Koo J: Psyche, opioids, and itch: therapeutic consequences. Dermatol. Ther. 18(4), 314-322 (2005).
108. Kimyai-Asadi A, Nousari HC, Kimyai-Asadi T, Milani F: Poststroke pruritus. Stroke 30(3), 692-693 (1999).
109. Wahlgren CF: Itch and atopic dermatitis: clinical and experimental studies. Acta Derm. Venereol. Suppl. (Stockh.) 165, 1-53 (1991).
110. Hagermark O, Wahlgren CF: Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. J. Dermatol. Sci. 4(2), 55-62 (1992).
111. Saurat JH: Dermatoporosis. The functional side of skin aging. Dermatology 215(4), 271-272 (2007).
112. Norman R: Xerosis and pruritus in the elderly. Dermatol. Ther. 16(3), 254-259 (2003).
113. Norman RA: Xerosis and pruritus in the elderly - recognition and management. In: Diagnosis of Aging Skin Diseases. Norman RA (Ed.). Springer Publishing, London, UK 151-159 (2008).
114. Bromm B, Scharein E, Darsow U, Ring J: Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci. Lett. 187(3), 157-160 (1995).
115. Fleischer AB: The Clinical Management of Itching. Fleischer AB (Ed.). Informa Healthcare, NY, USA (2000).
116. Hagermark O, Wahlgren CF: Treatment of itch. Semin. Dermatol. 14(4), 320-325 (1995).
117. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI: Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol. Appl. Skin Physiol. 13(6), 352-357 (2000).
118. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S: Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br. J. Dermatol. 148(6), 1212-1221 (2003).
119. Stander S, Luger T, Metze D: Treatment of prurigo nodularis with topical capsaicin. J. Am. Acad. Dermatol. 44(3), 471-478 (2001).
120. Wallengren J, Klinker M: Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J. Am. Acad. Dermatol. 32(2 Pt 1), 287-289 (1995).
121. Goldman D: Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J. Am. Acad. Dermatol. 44(6), 995-998 (2001).
122. Schurmeyer-Horst F, Fischbach R, Nabavi D, Metze D, Stander S: [Brachioradial pruritus: a rare, localized, neuropathic form of itching]. Hautarzt 57(6), 523-527 (2006).
123. Stander S, Luger TA: [Antipruritic effects of pimecrolimus and tacrolimus]. Hautarzt 54(5), 413-417 (2003).
124. Szepietowski JC, Reich A, Szepietowski T: Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther. Apher. Dial. 9(3), 277-279 (2005).
125. Dvorak M, Watkinson A, McGlone F, Rukwied R: Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm. Res. 52(6), 238-245 (2003).
126. Rukwied R, Watkinson A, McGlone F, Dvorak M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102(3), 283-288 (2003).
127. Eberlein B, Eicke C, Reinhardt HW, Ring J: Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J. Eur. Acad. Dermatol. Venereol. 22(1), 73-82 (2008).
128. Stander S, Reinhardt HW, Luger TA: [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Hautarzt 57(9), 801-807 (2006).
129. Phan NQ, Siepmann D, Gralow I, Stander S: Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J. Dtsch Dermatol. Ges. (2009) (Epub ahead of print).
130. Krause L, Shuster S: Mechanism of action of antipruritic drugs. BMJ Clin. Res. Ed. 287(6400), 1199-1200 (1983).
131. Nykamp D: Comparison of H1-antihistamines for pruritus in end-stage renal disease. Drug Intell. Clin. Pharm. 20(10), 806-807 (1986).
132. Kanai H, Nagashima A, Hirakata E et al.: The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci. 57(3), 207-213 (1995).
133. Matsui C, Ida M, Hamada M, Morohashi M, Hasegawa M: Effects of azelastin on pruritus and plasma histamine levels in hemodialysis patients. Int. J. Dermatol. 33(12), 868-871 (1994).
134. Aubia J, Aguilera J, Llorach I et al.: Dialysis pruritus: effect of cimetidine. J. Dial. 4(4), 141-145 (1980).
135. Weisshaar E, Dunker N, Rohl FW, Gollnick H: Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp. Dermatol. 13(5), 298-304 (2004).
136. Andoh T, Kuraishi Y: Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur. J. Pharmacol. 436(3), 235-239 (2002).
137. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Stander S: [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. Hautarzt 60(7), 564-568 (2009).
138. Dimkovic N, Djukanovic L, Radmilovic A, Bojic P, Juloski T: Uremic pruritus and skin mast cells. Nephron 61(1), 5-9 (1992).
139. Francos GC, Kauh YC, Gittlen SD et al.: Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int. J. Dermatol. 30(12), 884-889 (1991).
140. Pacor ML, Di Lorenzo G, Corrocher R: Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin. Exp. Allergy 31(10), 1607-1614 (2001).
141. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A: Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin. Exp. Allergy 34(9), 1401-1407 (2004).
142. Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE: The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch. Dermatol. 134(7), 785-786 (1998).
143. Friedmann PS, Palmer R, Tan E et al.: A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin. Exp. Allergy 37(10), 1536-1540 (2007).
144. Woodmansee DP, Simon RA: A pilot study examining the role of zileuton in atopic dermatitis. Ann. Allergy Asthma Immunol. 83(6 Part 1), 548-552 (1999).
145. Zabawski EJ Jr, Kahn MA, Gregg LJ: Treatment of atopic dermatitis with zafirlukast. Dermatol. Online J. 5(2), 10 (1999).
146. Wahlgren CF, Scheynius A, Hagermark O: Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm. Venereol. 70(4), 323-329 (1990).
147. Siepmann D, Luger TA, Stander S: Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J. Dtsch Dermatol. Ges. 6(11), 941-946 (2008).
148. Stander S, Weisshaar E, Luger TA: Neurophysiological and neurochemical basis of modern pruritus treatment. Exp. Dermatol. 17(3), 161-169 (2008).
149. Szepietowski JC, Morita A, Tsuji T: Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med. Hypotheses 58(2), 167-170 (2002).
150. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA: Relief of uremic pruritus with ultraviolet phototherapy. N. Engl. J. Med. 297(3), 136-138 (1977).
151. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann. Intern. Med. 91(1), 17-21 (1979).
152. Lazrak S, Skali H, Benchikhi H et al.: [Phototherapy and hemodialysis pruritus]. Nephrologie 25(7), 293-295 (2004).
153. Berne B, Vahlquist A, Fischer T, Danielson BG, Berne C: UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur. J. Clin. Invest. 14(3), 203-206 (1984).
154. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola: Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br. J. Dermatol. 147(5), 979-981 (2002).
155. Kaptanoglu AF, Oskay T: Ultraviolet B treatment for pruritus in Hodgkin's lymphoma. J. Eur. Acad. Dermatol. Venereol. 17(4), 489-490 (2003).
156. Samson Yashar S, Gielczyk R, Scherschun L, Lim HW: Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol. Photoimmunol. Photomed. 19(4), 164-168 (2003).
157. Karvonen J, Hannuksela M: Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm. Venereol. Suppl. (Stockh.) 120, 53-55 (1985).
158. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A: Treatment of aquagenic urticaria with PUVA and astemizole. J. Am. Acad. Dermatol. 36(1), 118-119 (1997).